Research programme: Huntington's disease gene therapy - Neurologix

Drug Profile

Research programme: Huntington's disease gene therapy - Neurologix

Alternative Names: AAV-dXIAP

Latest Information Update: 10 Jun 2014

Price : $50

At a glance

  • Originator Neurologix
  • Class Gene therapies
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease

Highest Development Phases

  • Discontinued Huntington's disease

Most Recent Events

  • 16 Mar 2012 Discontinued - Preclinical for Huntington's disease in USA (Intracerebral)
  • 02 Jun 2011 Preclinical development is ongoing in USA
  • 27 May 2011 Aegera Therapeutics has been acquired by Pharmascience
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top